Last reviewed · How we verify
NCT06548841
Development and Validation of (Bio)Sensors for the Identification of Pathogens
trial testing Nanobiotechnology platforms in Infections in 149 participants. Completed in 31 October 2025.
31 October 2025
Quick facts
| Lead sponsor | University of Bologna |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 149 |
| Start date | 30 May 2024 |
| Primary completion | 31 October 2025 |
| Estimated completion | 31 October 2025 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Nanobiotechnology platforms
Conditions studied
- Infections — all drugs for Infections →
- Infection, Bacterial — all drugs for Infection, Bacterial →
- Infection Viral — all drugs for Infection Viral →
- Infection, Parasite — all drugs for Infection, Parasite →
Sponsor
University of Bologna
Who can join
18 and older, any sex, with Infections or Infection, Bacterial. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The recent COVID-19 pandemic has revealed the need to develop tests that are accurate, rapid, and inexpensive for the diagnosis of infectious diseases. This problem is relevant not only for viruses, but also for bacteria and parasites: the identification of pathogens at low concentrations by simple and accurate methods is still largely unsatisfied because these microorganisms are structurally complex and are incorporated in composite and diverse biological samples, which can create relevant interferences in pathogens' detection. Direct diagnostic approaches, such as microscopic examination, culture and molecular testing are carried out in equipped laboratories and require long waiting times to obtain the results. Recently developed point-of-care (POC) tests are a group of technologies that miniaturize tests into portable devices such that they can be performed both in well-equipped laboratories and outside the conventional laboratory setting. The present study aims to explore the feasibility and adaptability of newly developed platforms to detect: 1. a virus (SARS-CoV2), 2. a bacterium (Pseudomonas aeruginosa) and 3. a protozoan parasite (Leishmania infantum) in clinical specimens, such as blood and respiratory samples. These newly developed platforms are expected to overcome the current limitations of molecular testing (high cost, time required and need for well-equipped laboratories) and rapid testing (high number of false-negative results). In addition, the newly developed platforms may have important clinical application in low-income countries, which will benefit from a simple and inexpensive approach to detect the many infectious diseases that affect millions of people each year.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06548841
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Infections
Currently open trials in the same condition.
- NCT07512141 — Single Versus Double Drains in the Axillary and Pectoral Regions After Modified Radical Mastectomy · NA · recruiting
- NCT07189858 — Light-Activated Antimicrobial Therapy to Prevent Surgical Site Infections - Canada · NA · active not recruiting
- NCT06426147 — L-citrulline to Improve Adverse Outcomes in Admitted Children (EChiLiBRiST, Clinical Trial 2, Inpatients) · NA · recruiting
- NCT06911658 — Infectious Complications After Esophagectomy · recruiting
- NCT06145724 — EnCoRe MoMS: Engaging Communities to Reduce Morbidity From Maternal Sepsis (Aim 1) · NA · recruiting
Other University of Bologna trials
Trials by the same sponsor.
- NCT07431047 — Fast-Track Protocol for Endovascular Aneurysm Repair (EVAR) of Infrarenal Abdominal Aortic Aneurysms · not yet recruiting
- NCT07295197 — Oral Indicators for ED Screening · recruiting
- NCT07198789 — Randomized, Double-blind Crossover Trial Comparing Low-GI Functional vs. Standard Wholegrain Carbohydrates on Glycolipid · NA · not yet recruiting
- NCT07127796 — Non-inferiority RCT on Fish Waste-Derived vs. Synthetic Vitamin D Supplementation in Healthy Adults With Suboptimal Vita · NA · not yet recruiting
- NCT07041060 — Evaluation of the Efficacy and Safety of Eolo in Patients With NERD · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06548841 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Bologna
- Last refreshed: 10 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06548841.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing